Is Retatrutide safe?
Emerging ResearchSide effects, risks, and safety considerations based on available research.
Research status
Retatrutide has some clinical data but research is still developing. Safety data exists but may come from small studies, short-term trials, or specific populations that may not reflect your situation.
Known concerns & side effects
- ⚠still in clinical development — not yet FDA approved
- ⚠only phase II data available; phase III trials are ongoing
- ⚠gastrointestinal side effects (nausea, diarrhea, vomiting) are common, especially during dose escalation
- ⚠long-term cardiovascular and safety data are not yet available
- ⚠weight regain after discontinuation is expected based on GLP-1 class data
- ⚠black market versions are already circulating with unknown contents
Use caution with
Relevant safety research
Retatrutide once weekly for treatment of obesity (TRIUMPH-2 Phase II)
Finding: At the highest dose (12mg), participants lost an average of 24.2% body weight at 48 weeks. All dose levels produced significantly greater weight loss than placebo.
Limitation: Phase II trial — smaller sample size and shorter duration than typical phase III trials required for approval. Long-term safety and durability of weight loss are unknown.
Frequently asked questions
Is it safe to buy Retatrutide online now?
No. Any product sold as retatrutide outside of clinical trials is unregulated and may contain incorrect doses, contaminants, or entirely different substances. There is no way to verify the contents of black market peptides. Wait for the approved pharmaceutical product.
How is Retatrutide different from semaglutide and tirzepatide?
Semaglutide (Ozempic/Wegovy) targets only GLP-1. Tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP. Retatrutide adds a third target — glucagon receptors — which increases energy expenditure and fat oxidation. Each generation has shown incrementally greater weight loss in clinical trials.
When will Retatrutide be available?
Eli Lilly is conducting phase III trials. If results are positive, FDA approval could come in 2026-2027, though timelines are uncertain. It is not currently available through any legitimate clinical channel outside of clinical trials.
Full Retatrutide Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2025-04-09
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.